CHF 189.00

Anti-Inflammatory or Anti-Rheumatic Drugs

Inglese · Copertina rigida

Spedizione di solito entro 6 a 7 settimane

Descrizione

Ulteriori informazioni

Our goal for this book is to examine the contemporary therapy of rheumatoid arthritis (RA) from the increasingly important perspective of impact upon quality of life, costs and long-term health outcomes. For too long the focus has been on short term, symptomatic, and surrogate indicator outcomes. Yet RA is a life-long disor der with the majority of impact on an individual patient many years following onset. Further, even in the short-term, researchers and rheumatologists have tended to emphasize measurements of disease activity such as joint counts, ESR and physi cian's opinion as to the amount of disease activity present. It is only relatively recently that measures of structural damage, quality of life and impact on broad domains of health have been given increasing emphasis. Also, the significance of early treatment of RA in order to optimise long-term outcomes has a relatively short history [1]. We have been focussed on the disease processes as surrogates for long term outcomes. Until the short-term process measures are validated as surrogates of long-term effects we should also turn our attention to outcomes of disease and the impact of our management on those outcomes [2). Inour view, this book is especially timely. We are at the dawn of a revolution in the management of RA and other complex immunological inflammatory disorders because their molecular, genetic and environmental mechanisms are being unrav elled. Inthe process, we are revealing a substantial number of novel and significant targets for pharmacotherapy.

Riassunto

This book gives a comprehensive overview of disease-modifying antirheumatic drugs (DMARDs). The introductory general chapters deal with the chemistry of DMARDs, their use in therapy, pharmacoeconomics, and a survey of opinion leaders in the field; the following specific chapters characterize each agent with regard to mechanism of action, therapy, pharmacology, efficacy, toxicity, and monitoring. For each agent some background is given, recent developments and influence of the treatment on patients` quality of life and long-term outcomes are presented.

Dettagli sul prodotto

Con la collaborazione di Richard O. Day (Editore), Daniel E. Furst (Editore), Piet L. van Riel (Editore), R. O. Day (Editore), D. E. Furst (Editore), P. L. V. Riel (Editore), Piet L.C.M. van Riel (Editore), Barry Bresnihan (Editore), Danie E Furst (Editore), Piet L C M van Riel et al (Editore), Piet L. C. M. Van Riel (Editore), Daniel E Furst (Editore)
Editore Springer, Basel
 
Contenuto Libro
Forma del prodotto Copertina rigida
Data pubblicazione 21.12.2004
Categoria Scienze naturali, medicina, informatica, tecnica > Medicina > Tematiche generali
 
EAN 9783764365950
ISBN 978-3-7643-6595-0
Numero di pagine 343
Altezza (della confezione) 24 cm
Peso (della confezione) 944 g
 
Serie Progress in Inflammation Research
Progress in Inflammation Research (PIR)
Progress in Inflammation Research
Progress in Inflammation Research (PIR)
Categorie B, Research, Medicine, Transplantation, Economics, Diseases, Therapy, Quality of Life, Pharmacology, Rheumatoid arthritis, Health Sciences, Medicine/Public Health, general, MEDICINAL CHEMISTRY, Toxicity, rheumatism
 

Recensioni dei clienti

Per questo articolo non c'è ancora nessuna recensione. Scrivi la prima recensione e aiuta gli altri utenti a scegliere.

Scrivi una recensione

Top o flop? Scrivi la tua recensione.

Per i messaggi a CeDe.ch si prega di utilizzare il modulo di contatto.

I campi contrassegnati da * sono obbligatori.

Inviando questo modulo si accetta la nostra dichiarazione protezione dati.